Literature DB >> 26775167

Neurological soft signs in euthymic bipolar I patients: A comparative study with healthy siblings and controls.

Amel Mrad1, Mohamed Wassim Krir2, Inès Ajmi2, Lotfi Gaha2, Anwar Mechri2.   

Abstract

Neurological Soft Signs (NSS) are endophenotypic markers widely studied in schizophrenia and remain poorly evaluated in bipolar disorder. The aims of this paper were to determine the prevalence and scores of NSS in bipolar I patients, compared to healthy siblings and controls and to explore correlations with socio-demographic and clinical features of patients. This was a case-control study comparing 92 euthymic bipolar I patients, 44 of their healthy siblings and 60 control subjects. The neurological assessment was performed through the NSS scale validated by Krebs et al. (2000). Bipolar I patients were also assessed with the Bech-Rafaelsen Mania Scale (MAS), the Hamilton Depression Rating Scale (HDRS) and the Global Assessment of Functioning (GAF). The raters were not blinded to groups. The prevalence and the total score of NSS were significantly higher in bipolar I patients compared to their healthy siblings and controls. The sibling group had significantly higher NSS prevalence and total score than controls. No correlation was found between NSS total score and socio-demographic and clinical features of patients, except a negative correlation with the school level and the GAF score. In conclusion, bipolar I patients have motor and sensory signs, which are unrelated to their clinical features.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bipolar I disorder; Case control study; Healthy siblings; Neurodevelopmental hypothesis; Neurological soft signs

Mesh:

Year:  2015        PMID: 26775167     DOI: 10.1016/j.psychres.2015.11.047

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  7 in total

Review 1.  Motor Abnormalities: From Neurodevelopmental to Neurodegenerative Through "Functional" (Neuro)Psychiatric Disorders.

Authors:  Victor Peralta; Manuel J Cuesta
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

2.  The Role of Intrinsic Brain Functional Connectivity in Vulnerability and Resilience to Bipolar Disorder.

Authors:  Gaelle E Doucet; Danielle S Bassett; Nailin Yao; David C Glahn; Sophia Frangou
Journal:  Am J Psychiatry       Date:  2017-08-18       Impact factor: 18.112

3.  Associations between Brain Structural Alterations, Executive Dysfunction, and General Psychopathology in a Healthy and Cross-Diagnostic Adult Patient Sample.

Authors:  Adrienne L Romer; Diego A Pizzagalli
Journal:  Biol Psychiatry Glob Open Sci       Date:  2021-06-12

Review 4.  Brain gyrification in bipolar disorder: a systematic review of neuroimaging studies.

Authors:  Alessandro Miola; Giulia Cattarinussi; Maria Lavinia Loré; Niccolò Ghiotto; Enrico Collantoni; Fabio Sambataro
Journal:  Brain Imaging Behav       Date:  2022-08-31       Impact factor: 3.224

5.  Clinical, Cognitive, and Neuroimaging Evidence of a Neurodevelopmental Continuum in Offspring of Probands With Schizophrenia and Bipolar Disorder.

Authors:  Gisela Sugranyes; Elena de la Serna; Roger Borras; Vanessa Sanchez-Gistau; Jose C Pariente; Soledad Romero; Inmaculada Baeza; Covadonga M Díaz-Caneja; Elisa Rodriguez-Toscano; Carmen Moreno; Miguel Bernardo; Dolores Moreno; Eduard Vieta; Josefina Castro-Fornieles
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

6.  Shared and Specific Intrinsic Functional Connectivity Patterns in Unmedicated Bipolar Disorder and Major Depressive Disorder.

Authors:  Ying Wang; Junjing Wang; Yanbin Jia; Shuming Zhong; Meiqi Niu; Yao Sun; Zhangzhang Qi; Ling Zhao; Li Huang; Ruiwang Huang
Journal:  Sci Rep       Date:  2017-06-15       Impact factor: 4.379

Review 7.  Neurological Soft Signs in Schizophrenia: An Update on the State- versus Trait-Perspective.

Authors:  Silke Bachmann; Johannes Schröder
Journal:  Front Psychiatry       Date:  2018-01-08       Impact factor: 4.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.